WATERTOWN, Mass., September 2, 2025 — Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, today announced a strategic discovery partnership with Jeevan Therapeutics, a biotechnology company founded by experienced industry leaders in biologics and small molecule development. The collaboration, valued at up to $200 million, will leverage Abkyu’s proprietary VHH discovery platform to accelerate the development of next-generation therapeutics aimed at addressing complex disease biology.

Under the agreement, Jeevan Therapeutics will gain dedicated access to Abkyu’s discovery platform and downstream engineering expertise to develop VHH candidates against its primary drug target. In return, Abkyu will receive an upfront payment and is eligible for additional regulatory and clinical milestone payments and commercial royalties.

“We couldn’t be more excited to partner with Jeevan Therapeutics,” said Travis LeGuyader, co-founder of Abkyu. “Our platform was built specifically to enable the kind of therapeutics their team is developing and is designed to significantly increase the chances of success by identifying molecules that precisely match the target product profiles (TPPs) they are pursuing. Partnering with Jeevan not only allows us to leverage our platform to help address a largely underserved patient population but also to align with a team that shares our vision for the potential of VHHs and the breadth of their therapeutic applications.”

“Partnering with Abkyu represents a pivotal step forward for Jeevan as we advance our mission to deliver transformative therapies for patients with significant unmet needs,” said Terrence West, CEO and Co-Founder of Jeevan Therapeutics. “Abkyu’s cutting-edge VHH discovery platform, combined with our expertise in precision biologics and drug development, positions us to accelerate the creation of next-generation therapies designed to improve long-term patient outcomes.”

This partnership reflects a shared vision to accelerate the development of next-generation biologics and expand treatment options for patients with significant unmet needs. By uniting Abkyu’s powerful VHH discovery platform with Jeevan’s innovative therapeutic strategy, the collaboration seeks to deliver therapies that set new standards for efficacy and long-term patient benefit.

About Jeevan Therapeutics, Inc.

Jeevan Therapeutics, based in Cambridge, MA, is a preclinical-stage biotechnology company developing precision medicines for colon disease, including autoimmune conditions and colorectal cancer. Our pipeline integrates advanced drug discovery, proprietary insights into immune-driven relapse, and strategic partnerships to deliver transformative therapies where current treatments fall short.

Our lead program focuses on an innovative antibody-drug conjugate (ADC) designed to prolong remission and reduce disease recurrence in Crohn’s disease. In parallel, our small-molecule program targets synthetic lethality to address significant unmet needs in colorectal cancer.

With deep scientific expertise and a collaborative development model, Jeevan Therapeutics is building a differentiated portfolio of therapies designed to redefine standards of care for patients living with colon disease.

About Abkyu, Inc.

Abkyu, Inc., based in Boston, MA, is a biotechnology company specializing in single-domain antibody (VHH) discovery, with a focus on some of the most challenging and high-value therapeutic targets, including GPCRs. Leveraging proprietary immunization strategies and advanced discovery methods, Abkyu’s approach enables broad diversity capture and utilizes cutting-edge bioinformatics to precisely identify and select the most promising clones. By combining deep scientific expertise with state-of-the-art workflows, Abkyu accelerates the development of next-generation biologics designed to tackle complex disease biology.